Sei Investments Co. Reduces Position in Pediatrix Medical Group, Inc. $MD

Sei Investments Co. decreased its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 19.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 157,407 shares of the company’s stock after selling 37,564 shares during the quarter. Sei Investments Co.’s holdings in Pediatrix Medical Group were worth $3,367,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MD. Cetera Investment Advisers grew its stake in Pediatrix Medical Group by 20.3% during the 1st quarter. Cetera Investment Advisers now owns 20,213 shares of the company’s stock valued at $432,000 after purchasing an additional 3,405 shares in the last quarter. First Trust Advisors LP increased its holdings in Pediatrix Medical Group by 4.6% during the 1st quarter. First Trust Advisors LP now owns 152,876 shares of the company’s stock worth $3,270,000 after purchasing an additional 6,769 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pediatrix Medical Group by 8.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,856,915 shares of the company’s stock valued at $82,496,000 after purchasing an additional 287,696 shares in the last quarter. Jennison Associates LLC raised its position in shares of Pediatrix Medical Group by 69.5% in the 1st quarter. Jennison Associates LLC now owns 60,846 shares of the company’s stock valued at $1,301,000 after purchasing an additional 24,950 shares in the last quarter. Finally, Gallacher Capital Management LLC purchased a new position in shares of Pediatrix Medical Group during the 1st quarter valued at approximately $222,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Truist Financial raised their price target on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $25.00 price target on shares of Pediatrix Medical Group in a report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a report on Friday, May 8th. Finally, UBS Group boosted their target price on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday. Two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $24.83.

Insider Activity

In other news, Director Shirley A. Weis sold 36,028 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 1.80% of the company’s stock.

Pediatrix Medical Group Price Performance

Shares of MD opened at $27.04 on Friday. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of 12.94 and a beta of 0.66. The stock has a 50 day moving average of $25.06 and a 200-day moving average of $22.63. The company has a current ratio of 1.32, a quick ratio of 1.33 and a debt-to-equity ratio of 0.45. Pediatrix Medical Group, Inc. has a 52 week low of $14.05 and a 52 week high of $27.94.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The business had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. During the same period in the prior year, the company posted $0.53 EPS. The business’s revenue was up 4.1% compared to the same quarter last year. As a group, analysts forecast that Pediatrix Medical Group, Inc. will post 2.1 EPS for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.